Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Neurology

• Publication date

  1998-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.50.3.669PMID 9521254
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A new look and feel

  1996cited by this paper
• Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease

  1996cited by this paper
• Apolipoprotein E allele–specific antioxidant activity and effects on cytotoxicity by oxidative insults and β–amyloid peptides

  1996cited by this paper
• Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease

  1996cited by this paper
• Alkaptonuria: such a long journey

  1996cited by this paper
• Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease

  1996cited by this paper
• Chemical ecology.

  1995cited by this paper
• Apolipoprotein E genotype in patients with alzheimer's disease: Implications for the risk of dementia among relatives

  1995cited by this paper
• Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease.

  1995cited by this paper
• Clinical outcomes and documentation of partial beneficial effects of immunotherapy for multiple sclerosis

  1995cited by this paper
• Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.

  1995cited by this paper
• Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic late‐onset alzheimer's disease

  1995cited by this paper
• Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease.

  1995cited by this paper
• Predicting Response to Cholinesterase Inhibitors in Alzheimer’s Disease

  1995cited by this paper
• The apolipoprotein E E4 allele and sex-specific risk of Alzheimer's disease.

  1995cited by this paper
• The role of dopamine D1-receptors in morphine-induced hyperlocomotion in mice.

  1994cited by this paper
• Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease.

  1994cited by this paper
• Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro.

  1994cited by this paper
• Tacrine alters the secretion of the beta‐amyloid precursor protein in cell lines

  1994cited by this paper
• A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.

  1994cited by this paper
• Predictive value of apolipoprotein E genotyping in Alzheimer's disease: Results of an autopsy series and an analysis of several combined studies

  1994cited by this paper
• APOE genotype does not modulate age of onset in families with chromosome 14 encoded Alzheimer's disease.

  1994cited by this paper
• Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats.

  1993cited by this paper
• Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

  1993cited by this paper
• Neurosurgical horizons in Parkinson's disease

  1993cited by this paper
• Ischaemic preconditioning: can the protection be bottled?

  1993cited by this paper
• Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

  1993cited by this paper
• Apolipoprotein E polymorphism and Alzheimer's disease.

  1993cited by this paper
• Apolipoprotein E genotype and Alzheimer's disease.

  1993cited by this paper
• Vitamin A supplementation in northern Ghana: effects on clinic attendances, hospital admissions, and child mortality

  1993cited by this paper
• Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.

  1993cited by this paper
• A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.

  1992cited by this paper
• Expression cloning of a Na(+)-independent neutral amino acid transporter from rat kidney.

  1992cited by this paper
• Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.

  1992cited by this paper
• Rationale for the planned clinical trials with nerve growth factor in Alzheimer's disease.

  1989cited by this paper
• Genesis and evolution of behavioral disorders: from infancy to early adult life.

  1984cited by this paper
• A new rating scale for Alzheimer's disease.

  1984cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Overview: the sex of the therapist.

  1982cited by this paper
• The Global Deterioration Scale for assessment of primary degenerative dementia.

  1982cited by this paper
• Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain.

  1982cited by this paper
• A cholinergic connection between normal aging and senile dementia in the human hippocampus.

  1977cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Creating Cultural and Lifestyle Awareness About Dementia and Co-morbidities

  2024cites this paper
• A case for seeking sex-specific treatments in Alzheimer’s disease

  2024cites this paper
• Overlooked Cases of Mild Cognitive Impairment: Implications to Early Alzheimer's Disease.

  2024cites this paper
• Bioética e medicina personalizada no envelhecimento: explorando complexidades

  2023cites this paper
• Bioética y medicina personalizada en el envejecimiento: explorar las complejidades

  2023cites this paper
• Intersectionality in Alzheimer’s Disease: The Role of Female Sex and Black American Race in the Development and Prevalence of Alzheimer’s Disease

  2023cites this paper
• Bioethics and concierge medicine in aging: exploring complexities

  2023cites this paper
• Sex and gender differences in Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis: a narrative review.

  2023cites this paper
• Alzheimer's disease phenotype based upon the carrier status of the apolipoprotein E ɛ4 allele

  2023cites this paper
• Validated LC/MS/MS Method for the Determination of Rivastigmine in Human Plasma: Application to a Pharmacokinetic Study in Egyptian Volunteers to Determine the Effect of Gender and Body Mass Index.

  2022cites this paper
• Human microRNA (miR-20b-5p) modulates Alzheimer’s disease pathways and neuronal function, and a specific polymorphism close to the MIR20B gene influences Alzheimer’s biomarkers

  2022cites this paper
• Considering Biological Sex in Traumatic Brain Injury

  2021cites this paper
• Precision health in Alzheimer disease: Risk assessment‐based strategies

  2021cites this paper
• Sex and gender differences in genetic and lifestyle risk and protective factors for dementia

  2021cites this paper
• Acute response to cholinergic challenge predicts long‐term response to galantamine treatment in patients with Alzheimer's disease

  2021cites this paper
• Emerging Promise of Immunotherapy for Alzheimer's Disease: A New Hope for the Development of Alzheimer's Vaccine.

  2020cites this paper
• Pharmacogenomic approaches to the treatment of sporadic Alzheimer’s disease

  2020cites this paper
• Mitochondria-Targeted Therapeutics for Alzheimer's Disease: The Good, the Bad, the Potential

  2020cites this paper
• Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease

  2020cites this paper
• M1 muscarinic receptor is a key target of neuroprotection, neuroregeneration and memory recovery by i-Extract from Withania somnifera

  2019cites this paper
• Preliminary Report on the Feasibility and Efficacy of the Modified Atkins Diet for Treatment of Mild Cognitive Impairment and Early Alzheimer’s Disease

  2019cites this paper
• Sex and Gender Driven Modifiers of Alzheimer’s: The Role for Estrogenic Control Across Age, Race, Medical, and Lifestyle Risks

  2019cites this paper
• Molecular differences in Alzheimer's disease between male and female patients determined by integrative network analysis

  2018cites this paper
• Sex differences in Alzheimer disease — the gateway to precision medicine

  2018cites this paper
• Effect of Apolipoprotein E ɛ4 Carrier Status on Cognitive Response to Acetylcholinesterase Inhibitors in Patients with Alzheimer’s Disease: A Systematic Review and Meta-Analysis

  2018cites this paper
• Effectiveness of a Personalized Brain-Computer Interface System for Cognitive Training in Healthy Elderly: A Randomized Controlled Trial

  2018cites this paper
• Rexinoids as Therapeutics for Alzheimer's Disease: Role of APOE.

  2017cites this paper
• Sex and gender differences in the treatment of Alzheimer's disease: A systematic review of randomized controlled trials

  2017cites this paper
• Arabidopsis thaliana extracts optimized for polyphenols production as potential therapeutics for the APOE-modulated neuroinflammation characteristic of Alzheimer’s disease in vitro

  2016cites this paper
• Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice.

  2016cites this paper
• Apolipoprotein E ε-4 as a genetic determinant of Alzheimer’s disease heterogeneity

  2015cites this paper
• APOE‐modulated Aβ‐induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective

  2015cites this paper
• Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases

  2015cites this paper
• Pharmacogenomic Approaches to the Treatment of Sporadic Alzheimer Disease using Cholinomimetic Agents

  2015cites this paper
• Reference and working memory deficits in the 3xTg-AD mouse between 2 and 15-months of age: a cross-sectional study.

  2015cites this paper
• APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer’s Disease

  2015cites this paper
• Cognitive Subdomain Responses to Galantamine in Alzheimer’s Disease

  2014cites this paper
• The Effect of APOE &egr;4 Allele on Cholinesterase Inhibitors in Patients With Alzheimer Disease: Evaluation of the Feasibility of Resting State Functional Connectivity Magnetic Resonance Imaging

  2014cites this paper
• Application of Pharmacogenomics in Global Alzheimer’s Disease Clinical Trials and Ethical Implications

  2014cites this paper
• Activity Modulate Retinoid X Receptor Agonist Genotype APOE Pathology and β Amyloid-Molecular Bases of Disease :

  2014cites this paper
• Amyloid-β Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in Vivo*

  2014cites this paper
• Butyrylcholinesterase K and apolipoprotein ε4 affect cortical thickness and neuropsychiatric symptoms in Alzheimer's disease.

  2014cites this paper
• The potential applications of Apolipoprotein E in personalized medicine

  2014cites this paper
• Reduced plasticity and mild cognitive impairment-like deficits after entorhinal lesions in hAPP/APOE4 mice.

  2013cites this paper
• Accelerated Cell Aging in Female APOE-ε4 Carriers: Implications for Hormone Therapy Use

  2013cites this paper
• Personalized medicine in context: social science perspectives

  2013cites this paper
• Alzheimer's Disease

  2013cites this paper
• Effect of CYP2D6*10 and APOE Polymorphisms on the Efficacy of Donepezil in Patients With Alzheimer's Disease

  2013cites this paper
• Apolipoprotein E, gender, and Alzheimer’s disease: an overlooked, but potent and promising interaction

  2013cites this paper
• Racial and ethnic disparities in Alzheimer's disease pharmacotherapy exposure: an analysis across four state Medicaid populations.

  2012cites this paper
• Cholinesterase Inhibitors for Alzheimer’s Disease

  2012cites this paper
• Pharmacogenetics and the pharmacy profession : a sociological exploration

  2012cites this paper
• Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease

  2011cites this paper
• Immunotherapy for Alzheimer’s disease

  2011cites this paper
• Apolipoprotein E in Alzheimer's disease and other neurological disorders.

  2011cites this paper
• BCHE and CYP2D6 genetic variation in Alzheimer’s disease patients treated with cholinesterase inhibitors

  2011cites this paper
• Pharmacogenetics, Pharmacogenomics, and Individualized Medicine

  2011cites this paper
• Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease.

  2011cites this paper
• Pharmacogenomics in neurology: Current state and future steps

  2011cites this paper
• Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease.

  2010cites this paper
• Role of pharmacogenomics in the drug development.

  2010cites this paper
• The perils of Alzheimer's drug development.

  2009cites this paper
• Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story

  2009cites this paper
• Role of pharmacogenomics in the drug development.

  2009cites this paper
• Genetics in clinical trials.

  2009cites this paper
• Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

  2008cites this paper
• Effect of ApoE Genotype on Response to Donepezil in Patients with Alzheimer’s Disease

  2008cites this paper
• Geschlechtsspezifische Unterschiede der Alzheimer Demenz

  2008cites this paper
• Long-Term Treatment Response, Predictors and Biochemical Markers in Alzheimer's Disease

  2008influential citation
• White matter lesions in the elderly: pathophysiological hypothesis on the effect on brain plasticity and reserve.

  2008cites this paper
• Commentary on “A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium.” Prevention of dementia: A few heretical proposals

  2008cites this paper
• Pharmacogenomics and the Treatment of Sporadic Alzheimers Disease:A Decade of Progress

  2008cites this paper
• Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease.

  2008cites this paper
• [Sex differences in Alzheimer's disease].

  2008cites this paper
• Cognitive Predictors of Donepezil Therapy Response in Alzheimer Disease

  2007cites this paper
• Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer’s disease

  2007cites this paper
• ApoE-dependent plasticity in Alzheimer’s disease

  2007cites this paper
• Genomics and proteomics are changing discovery, development and clinical use of dementia drugs

  2007cites this paper
• Neurorehabilitation in dementia on the move : Influences of physical activity on cognition, mood, and the rest-activity rhythm

  2007cites this paper
• Leczenie choroby Alzheimera: czy istnieją możliwości przewidywania klinicznej odpowiedzi na inhibitory cholinesterazy?

  2006cites this paper
• Investigating gender differences in outcome following severe traumatic brain injury in a predominantly Asian population

  2006cites this paper
• Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.

  2006cites this paper
• Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease.

  2006cites this paper
• Drug Class Review on Alzheimer's Drugs

  2006cites this paper
• Pharmacogenetics as Alien Science

  2006influential citation
• Alzheimer Disease and Its Management: A Review

  2006cites this paper
• The Primary Care of Alzheimer Disease

  2006cites this paper
• Dimeric and hybrid anti-Alzheimer drug candidates.

  2006cites this paper
• Metrifonate: A Cholinesterase Inhibitor for Alzheimer's Disease Therapy

  2006cites this paper
• Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism.

  2006cites this paper
• Neuroanatomical predictors of response to donepezil therapy in patients with dementia.

  2005cites this paper
• Neurodegenerative Disorders: The Role of Genetic Factors in Their Origin and the Efficiency of Treatment

  2005cites this paper
• Do Vascular Lesions and Related Risk Factors Influence Responsiveness to Donepezil Chloride in Patients with Alzheimer’s Disease?

  2005cites this paper
• Effect of the Apolipoprotein E ε4 Allele on the Efficacy and Tolerability of Galantamine in the Treatment of Alzheimer’s Disease

  2005cites this paper
• Vitamin E and donepezil for the treatment of mild cognitive impairment.

  2005cites this paper
• Medial Temporal Lobe Atrophy and APOE Genotype Do Not Predict Cognitive Improvement upon Treatment with Rivastigmine in Alzheimer’s Disease Patients

  2005cites this paper
• Lifelong endocrine fluctuations and related cognitive disorders.

  2005cites this paper
• Responsiveness to cholinesterase inhibitors in Alzheimer's disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene.

  2005cites this paper
• The Politics of Personalised Medicine: The personalised is political

  2004cites this paper
• The Clinical Efficacy and Safety of Galantamine in the Treatment of Alzheimer's Disease

  2004cites this paper